New adolescent vaccination recommendations and how to make them "stick"

被引:11
作者
Middleman, Amy B.
机构
[1] Texas Childrens Hosp, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Pediat, Adolescent Med & Sports Med Sect, Houston, TX 77030 USA
关键词
adolescent immunizations; human papillomavirus; quadrivalent meningococcal vaccine; school mandates; tetanus; diphtheria and acellular pertussis vaccine; varicella;
D O I
10.1097/MOP.0b013e3281e72cd2
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Purpose of review Multiple vaccination recommendations have recently targeted the adolescent age group. It is important for providers to be aware of all new recommendations, the rationale for the recommendations, and how to best implement recommendations for this age group. Recent findings The 11 - 12-year-old immunization platform now includes vaccination against tetanus, diphtheria, pertussis (tetanus, diphtheria and acellular pertussis or Tdap vaccine), meningococcal disease (conjugate meningococcal vaccine), human papillomavirus (for females), and a second varicella vaccination for those who have received one vaccination and have not had disease. Any missing vaccinations should be updated at this time. Many strategies exist to improve adherence to adolescent recommendations; the school mandate is an important yet controversial strategy that is being hotly debated in the literature. Summary There are many exciting, new vaccines for adolescents. It is important to improve vaccination coverage within the adolescent age group. Immunization against disease has previously been viewed as a primarily childhood issue, yet with ever-evolving technology and the need to vaccinate against diseases affecting all ages, vaccination strategies for adolescents need to be reviewed and improved. Mandates, when initiated with care, are one of the most effective implementation strategies for adolescents.
引用
收藏
页码:411 / 416
页数:6
相关论文
共 45 条
[21]   Papillomavirus vaccines in clinical trials [J].
Galloway, DA .
LANCET INFECTIOUS DISEASES, 2003, 3 (08) :469-475
[22]  
*GLAXOSMITHKLINE, 2005, PROD INF TET TOX RED
[23]  
Hahn Robert, 2007, MMWR Recomm Rep, V56, P1
[24]   Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial [J].
Harper, DM ;
Franco, EL ;
Wheeler, CM ;
Moscicki, AB ;
Romonowski, B ;
Roteli-Martins, CM ;
Jenkins, D ;
Schuind, A ;
Clemens, SAC ;
Dubin, G .
LANCET, 2006, 367 (9518) :1247-1255
[25]   Effect of middle school entry requirements on hepatitis B vaccination coverage [J].
Jacobs, RJ ;
Meyerhoff, AS .
JOURNAL OF ADOLESCENT HEALTH, 2004, 34 (05) :420-423
[26]   Access to medical care for adolescents: Results from the 1997 Commonwealth Fund Survey of the Health of Adolescent Girls [J].
Klein, JD ;
Wilson, KM ;
McNulty, M ;
Kapphahn, C ;
Collins, KS .
JOURNAL OF ADOLESCENT HEALTH, 1999, 25 (02) :120-130
[27]  
KOUTSKY J, 1997, AM J MED, V5, P3
[28]  
Kretsinger Katrina, 2006, Morbidity and Mortality Weekly Report, V55, P1
[29]  
LOWRY DR, 2006, J CLIN INVEST, V116, P1167, DOI DOI 10.1172/JC128607
[30]   Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy [J].
Manhart, Lisa E. ;
Holmes, King K. ;
Koutsky, Laura A. ;
Wood, Troy R. ;
Kenney, Donna L. ;
Feng, Qinghua ;
Kiviat, Nancy B. .
SEXUALLY TRANSMITTED DISEASES, 2006, 33 (08) :502-508